Pan African Medical Journal
Journal / Pan African Medical Journal / Vol. 43 No. 1 (2022) / Articles

download PDF

Published:

Oct 11, 2022

Keywords:

Hepatitis C virus Ag; chronic hepatitis; cirrhosis; hepatocellular carcinoma

Issue

Vol. 43 No. 1 (2022)

Section

Articles

Brief summary of the agreement Anyone is free: · to copy, distribute, and display the work; · to make derivative works; · to make commercial use of the work; Under the following conditions: Attribution · the original author must be given credit; · for any reuse or distribution, it must be made clear to others what the license terms of this work are; · any of these conditions can be waived if the authors gives permission. Statutory fair use and other rights are in no way affected by the above

Donatien Serge Mbaga

Department of Microbiology, The University of Yaoundé I, Yaoundé, Cameroon

Jacky Njiki Bikoï

Department of Microbiology, The University of Yaoundé I, Yaoundé, Cameroon

Etienne Atenguena Okobalemba

Faculty of Medicine and Biomedical Sciences, The University of Yaoundé I, Yaoundé, Cameroon

Justin Olivier Essindi

Department of Microbiology, The University of Yaoundé I, Yaoundé, Cameroon

Chris André Mbongue Mikangue

Department of Microbiology, The University of Yaoundé I, Yaoundé, Cameroon

Alexandra Emmanuelle Membangbi

Department of Microbiology, The University of Yaoundé I, Yaoundé, Cameroon

Aïcha Ngoutane

Department of Microbiology, The University of Yaoundé I, Yaoundé, Cameroon; Institute of Medical Research and Medicinal Plant Study, Yaoundé, Cameroon

Arnaud Franck Elang

Department of Microbiology, The University of Yaoundé I, Yaoundé, Cameroon

Sabine Aimée Touangnou-Chamda

Department of Microbiology, The University of Yaoundé I, Yaoundé, Cameroon

Carole Stéphanie Sake

Department of Microbiology, The University of Yaoundé I, Yaoundé, Cameroon

George Ikomey Mondinde

Faculty of Medicine and Biomedical Sciences, The University of Yaoundé I (Center for the Study and Control of Communicable Diseases (CSCCD), Yaoundé, Cameroon

Sebastien Kenmoe

Department of Microbiology and Parasitology, University of Buea, Buea, Cameroon

Sara Honorine Riwom Essama

Department of Microbiology, The University of Yaoundé I, Yaoundé, Cameroon

Abstract

Introduction: epidemiological data suggests that more than 50% of hepatitis C virus (HCV) patients fail treatment. The objective of the study was to highlight the seroprevalence of hepatitis C virus antigen (HCV Ag) at the 12^th week of treatment.

Methods: during a cross-sectional study, participants with chronic liver disease and hepatocellular carcinoma (HCC) were recruited between December 2020 and March 2022 at the Yaoundé General Hospital (HGY) and the University Teaching Hospital of Yaounde (UTHY). Five millilitres of blood samples were taken from each consenting participant and then a qualitative search for HCV Ag by Enzyme-Linked Immuno Assay (ELISA) was performed. Analysis of the results was performed using SPSS Version 25.0 software.

Results: out of the 192 participants selected for the study, only 92 (47,9%) participants were at 12 weeks of treatment, including 69 (75%) participants positive for the hepatitis C virus antibody (HCV Ab) by RDT. Of these participants, 44 (47.8%) participants were positive for HCV Ag by ELISA, respectively 19/37 (51.3%), 14/19 (73.6%), 11/13 (84.6%) with chronic hepatitis (HC), Cirrhosis, and HCC (P<0.0001).

Conclusion: our results showed a high prevalence of HCV Ag in patients at their 12^th week of treatment which predicts treatment failure and calls for public policy to develop new management strategies to prevent HCV treatment failure in our context.

Journal Identifiers

eISSN: 1937-8688